Celltrion, Inc.
068270
Rank in Stocks
#720
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the... Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.
Share Price
$146.63
Market Cap
$33.44B
Change (1 day)
-1.52%
Change (1 year)
23.60%
Country
KR
Trade Celltrion, Inc. (068270)
Category
Healthcare
P/E ratio for Celltrion, Inc. (068270)
P/E ratio as of October 2026 TTM: 28.04
According to Celltrion, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 28.04. At the end of 2024 the company had a P/E ratio of 92.56.
P/E ratio history for Celltrion, Inc. from 2007 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 28.04 | -27.35% |
| 2025 | 38.60 | -58.30% |
| 2024 | 92.56 | 63.86% |
| 2023 | 56.49 | 50.14% |
| 2022 | 37.62 | -13.68% |
| 2021 | 43.59 | -49.66% |
| 2020 | 86.58 | 17.79% |
| 2019 | 73.50 | -27.70% |
| 2018 | 101.67 | 45.28% |
| 2017 | 69.98 | 3.21% |
| 2016 | 67.81 | 14.08% |
| 2015 | 59.44 | 63.44% |
| 2014 | 36.37 | -7.90% |
| 2013 | 39.49 | 144.93% |
| 2012 | 16.12 | -30.49% |
| 2011 | 23.19 | -26.64% |
| 2010 | 31.61 | 30.71% |
| 2009 | 24.18 | -60.52% |
| 2008 | 61.26 | 778.09% |
| 2007 | 6.98 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 30.83 | 9.95% |
US
|
|
| -29.16 | -204.00% |
US
|
|
| -25.99 | -192.69% |
AU
|
|
| 22.43 | -20.00% |
BE
|
|
| 31.22 | 11.32% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.